JPH05503428A - pharmaceuticals - Google Patents
pharmaceuticalsInfo
- Publication number
- JPH05503428A JPH05503428A JP3505507A JP50550791A JPH05503428A JP H05503428 A JPH05503428 A JP H05503428A JP 3505507 A JP3505507 A JP 3505507A JP 50550791 A JP50550791 A JP 50550791A JP H05503428 A JPH05503428 A JP H05503428A
- Authority
- JP
- Japan
- Prior art keywords
- ammonium sulfate
- solution
- formula
- buffer
- penicillium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
- C12P7/04—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/62—Carboxylic acid esters
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
(57)【要約】本公報は電子出願前の出願データであるため要約のデータは記録されません。 (57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.
Description
【発明の詳細な説明】 医薬品 本発明は、抗ウィルス活性を有する化合物の製造に宵月な中間体の製造法に関す る。[Detailed description of the invention] pharmaceuticals The present invention relates to a method for producing an intermediate that is useful for producing compounds with antiviral activity. Ru.
εP−A−141927(ビーチャムグループ)は化合物ベンシクロビル(pe nciclovir)と抗ウィルス剤としてのその使用を開示しており、EP− A−182024(ビーチャムグループ)はそのプロドラッグであるフェンシク ロビル(faa+ciclovir)を開示している。εP-A-141927 (Beacham Group) is the compound benciclovir (pe nciclovir) and its use as an antiviral agent, EP- A-182024 (Beacham Group) is its prodrug Phensic. Lovir (faa+ciclovir) is disclosed.
ベンシクロビルとフェンシクロビルはそれぞれ式(A)および(B):HO−C H2−0! −ClI2− OHで表される。Benciclovir and fenciclovir have formulas (A) and (B), respectively: HO-C H2-0! It is represented by -ClI2-OH.
上記化合物の製造法は、式(C): の2−アミノ−6−クロロプリンと式CD):[式中、Q ハヒドロキシやハロ (例えばヨードまたはブロモ)のような離脱基である1の側鎖中間体との反応を 包含する。The method for producing the above compound is represented by formula (C): 2-amino-6-chloropurine and formula CD): [wherein Q is hydroxy or halo reaction with a side chain intermediate of 1 that is a leaving group (such as iodo or bromo) include.
式(D)の側鎖中間体は簡単には入手できず、多段合成によって製造される。Q をアセテートで置き換えた式(D)の化合物、すなわち式(1)・の化合物は、 W、J、 Ba1ley at al、、 J、 Org、 Chem、、 1 962に記載の方法の変法を使って、市販のトリエチル1.1.2−エタントリ カルボキシレートから製造することができるが、アセトキシ基の1つを離脱基に 選択的に変換することは不可能である。なぜなら、それらは全て同じような化学 的環境にあり、化学的加水分解がこれらの官能基を識別できるとは思えないから である。Side chain intermediates of formula (D) are not readily available and are produced by multi-step synthesis. Q The compound of formula (D) in which is replaced with acetate, that is, the compound of formula (1), is W, J, Ba1ley at al, J, Org, Chem, 1 Commercially available triethyl 1.1.2-ethanetri It can be prepared from carboxylates, but one of the acetoxy groups is used as a leaving group. It is not possible to convert selectively. Because they all have similar chemistry chemical hydrolysis is unlikely to be able to distinguish between these functional groups. It is.
微生物のヒドロラーゼ(加水分解酵素)を使って式([)の化合物、すなわちト リアセテートを式([I) : のジアセテートに変換する新規な方法が今回開発された。Using microbial hydrolases, compounds of the formula ([), i.e. Reacetate is expressed by the formula ([I): A new method has now been developed to convert diacetate into diacetate.
かくして、本発明は、先に定義した式(1)の化合物を微生物のヒドロラーゼで 処理することからなる、先に定義した式(I【)の化合物の製造法を提供する。Thus, the present invention provides that the compound of formula (1) as defined above is treated with a microbial hydrolase. Provided is a method for the preparation of a compound of formula (I) as defined above, comprising the steps of:
適当な微生物ヒドロラーゼはペニシリウム属およびバクテリウム属を含めた微生 物中に見いだされ、特にペニシリウム・フレクエンタンス(Penici ll iumfrequentans) IMI 92265に由来するものである。Suitable microbial hydrolases include microorganisms of the genus Penicillium and Bacterium. It is found in many things, especially Penicillium frequentans (Penicillium ium frequency) is derived from IMI 92265.
微生物は栄養培地または他の適当な培地で10−50°Cの温度、好ましくは約 20−40°Cにて、使用する微生物の性質に応じて増殖させる。反応はこの培 地中で、あるいは細胞の分離および移動後に別の培地または塩溶液中で行うこと ができる。The microorganism is grown in a nutrient medium or other suitable medium at a temperature of 10-50°C, preferably about Grow at 20-40°C, depending on the nature of the microorganism used. The reaction Can be done underground or in a separate medium or salt solution after cell separation and transfer Can be done.
また、細胞の破壊および分画化後に精製したまたは部分Wi!!!!シた酵素を 使用することもできる。Also, purified or partial Wi! after cell disruption and fractionation! ! ! ! Shit enzyme You can also use
この反応は3−1Oのpl範囲、好ましくはPH5,0−8,0で、通常10− 40°Cの温度、好ましくは20−40℃にて実施する。The reaction is carried out at a pl range of 3-10, preferably at a pH of 5,0-8,0, usually 10- It is carried out at a temperature of 40°C, preferably 20-40°C.
酵素変換反応は硫酸アンモニウム(好ましくは1モル)の存在下で収量を改善す ることができる。Enzymatic conversion reactions can be performed in the presence of ammonium sulfate (preferably 1 mol) to improve yields. can be done.
一般的には、細胞に結合したまたは細胞を含まない形の酵素を固定化して、それ を再使用することができる。ペニシリウム・フレクエンタンス[MI 9226 5の場合には、有意な活性の低下なしに数回実施することができる。基質濃度は 1%(W/V)またはそれ以上に高めてもよい。かくして、円柱形のループ反応 器または同様の反応器中の固定化酵素に基質を通過させる連続製造法が意図され る。Typically, enzymes are immobilized in cell-bound or cell-free form; can be reused. Penicillium frequentans [MI 9226 In case 5, it can be carried out several times without significant loss of activity. The substrate concentration is It may be increased to 1% (W/V) or more. Thus, the cylindrical loop reaction Continuous manufacturing methods are contemplated in which the substrate is passed through an immobilized enzyme in a reactor or similar reactor. Ru.
生成物は適当な溶媒抽出により精製し、その後場合によりクロマトグラフィーに かけてもよい。The product is purified by extraction with a suitable solvent, followed by optional chromatography. You can put it on.
この製法は最小限の式(III)の副生物が製造されるという利点を育する。This process offers the advantage that minimal by-products of formula (III) are produced.
以下の実施例は本発明を例示するものである。既知の技法を使って微生物株の改 良を行うことにより、収量を増加し得ることが理解されるであろう。The following examples illustrate the invention. Modification of microbial strains using known techniques It will be appreciated that yields can be increased by doing better.
実施例1 ペニシリウム・フレクエンタンスtMI 92265の培養ペニシリウム・フレ クエンタンスIMI 92265の斜面からの白金耳2杯分の菌糸体を4mlの 0.0渡Tween 80/水中で混合し、その懸濁液2mlを250m1エル レンマイヤーフラスコ中の種培地40 mlに接種した。種培地(%冑/V)は pH5,2に調整した脱イオン水中のトウモロコシ浸出液(4%)、糖蜜(2, 6%) 、CaCO5(0,5%)およびdjstillers’ 5olub les (Scotafeed) (2%)から成っていた。24Orpm、 28°Cで72時時間上う培養後、種ブロス1,5mlを250 mlエルレシ ンマイヤーフラスコ中生産用培地40m1に接種した。この生産用培地(%W/ V)はpH5,6に調整した脱イオン水中のグルコース(瀉)、栄養ブロス(0 ,8%)、酵母エキス(0,2%)および麦芽エキス(0,3%)から成ってい た。これらのフラスコを240 rpm、 28°Cで振とうしながら72時間 インキュベートした。Example 1 Culture of Penicillium flexentans tMI 92265 Add 2 cups of mycelium from the slope of Quentance IMI 92265 to 4ml. Mix 0.0% Tween 80/water and add 2ml of the suspension to 250ml 40 ml of seed medium in a Renmeyer flask was inoculated. Seed medium (%cold/V) is Corn infusion (4%), molasses (2,2%) in deionized water adjusted to pH 5,2 6%), CaCO5 (0,5%) and djstillers’5olub les (Scotafeed) (2%). 24Orpm, After incubation for 72 hours at 28°C, add 1.5 ml of seed broth to 250 ml 40 ml of production medium was inoculated in a Mayer flask. This production medium (%W/ V) Glucose in deionized water adjusted to pH 5,6, nutrient broth (0 ,8%), yeast extract (0,2%) and malt extract (0,3%). Ta. These flasks were incubated at 240 rpm and 28°C for 72 hours with shaking. Incubated.
実施例2 ペニシリウム・フレクエンタンス[M[92265の全細胞による位置選択的エ ステル加水分解 実施例1のように生産したペニシリウム・フレクエンタンスrMI 92265 の培養振とうフラスコに式(1)のトリアセテートを加えて、最終基質濃度を4 IIIg/mlとした。その後、このフラスコを240 rpm 28℃で振 とうし、遠心分離および上清のクロロホルム抽出後に生成物について検定した。Example 2 Regioselective activation by whole cells of Penicillium frequentans [M[92265] stell hydrolysis Penicillium frequentans rMI 92265 produced as in Example 1 Triacetate of formula (1) was added to the culture shake flask to bring the final substrate concentration to 4. It was set as IIIg/ml. Afterwards, shake the flask at 240 rpm at 28°C. The product was assayed after milling, centrifugation and chloroform extraction of the supernatant.
有機相はHPLCで検定した。The organic phase was assayed by HPLC.
基質と微生物を6時間インキュベートした後に、基質のジアセテート生成物(1 1)への15%転化が見られ、生成物(■1)対その位置異性体([lDの比は 919であった。9時間のインキュベーション後、生成物への6%転化が見られ 、生成物(II)対その位置異性体(III)の比は97:3であった。After incubating the substrate and microorganism for 6 hours, the diacetate product of the substrate (1 1) was observed, and the ratio of product (■1) to its positional isomer ([lD is It was 919. After 9 hours of incubation, 6% conversion to product was observed. , the ratio of product (II) to its regioisomer (III) was 97:3.
実施例1のように生産したペニシリウム・フレクエンタンス1組92265の培 養ブロス1.6Lから、4℃に冷却後遠心(16,000X g、 10分、4 ℃)して菌糸体を分離した。このバイオマスを0.1M トリス緩衝液(pH7 ,5)中に再懸濁して650 mlとなし、細胞スラリーの60m1バツチでフ レンチプレス(12509Si)を用いて細胞を破壊した。遠心(23,000 X g、 20分、4℃)後、上滑に1M水酸化ナトリウム溶液を加えてpH7 ,1に調整し、水5mlに溶解したストレプトマイシン硫酸塩3゜65gの溶液 を攪拌しながら加えた。0°Cで0.5時間後、細胞抽出物を遠心(39゜00 0 X g、 20分、4℃)し、分離した上清に固体の硫酸アンモニウムを撹 拌しながら加えて硫酸アンモニウムの60%飽和濃度にした。0℃で15分後、 遠心(23,000x g、 10分、4°C)シ、分離した上滑を前のように 硫酸アンモニウムの80%飽和にした。0℃で15分後、前のように再遠心し、 上溝を分離して沈殿物を残し、これを25III&Iトリス緩衝液(pH7,5 ) 7.5 mlに溶解した。この溶液を製造者の指示に従ってセファデックス PDIOカラムにかけ、25−トリス緩衝液(pH7,5)で溶離して脱塩した 。脱塩タンパク質調製物は脱イオン水で最高20m1の容量となし、25III Mトリス緩衝液CpH7,5)で予め平衡化しておいたアニオン交換樹脂カラム (DEAε−Trisacryl、 7.5 X 1.8 cm)にかけた。溶 離はこの緩衝液と、8時間にわたり、同じ緩衝液中の0−300 aI&l硫酸 アンモニウム溶液の直線勾配を用いて行った。A culture of Penicillium flexentans 92265 produced as in Example 1. From 1.6 L of culture broth, cool to 4°C and centrifuge (16,000 x g, 10 minutes, 4 ℃) to isolate mycelium. This biomass was mixed with 0.1M Tris buffer (pH 7). , 5) to make a total volume of 650 ml, and filter with 60 ml batches of cell slurry. Cells were disrupted using Lentipress (12509Si). Centrifugation (23,000 x g, 20 minutes, 4°C), add 1M sodium hydroxide solution to the top layer to pH 7. , a solution of 3.65 g of streptomycin sulfate dissolved in 5 ml of water. was added while stirring. After 0.5 h at 0°C, the cell extract was centrifuged (39°00 0 × g, 20 min, 4°C), and solid ammonium sulfate was stirred into the separated supernatant. The mixture was added with stirring to reach a 60% saturation concentration of ammonium sulfate. After 15 minutes at 0℃, Centrifuge (23,000 x g, 10 min, 4°C) and remove the separated supernatant as before. 80% saturation of ammonium sulfate was achieved. After 15 min at 0°C, recentrifuge as before. Separate the upper groove to leave the precipitate, which is added to 25III&I Tris buffer (pH 7,5). ) Dissolved in 7.5 ml. Add this solution to Sephadex according to the manufacturer's instructions. It was applied to a PDIO column and desalted by elution with 25-Tris buffer (pH 7.5). . Desalted protein preparations up to a volume of 20ml with deionized water, 25III Anion exchange resin column pre-equilibrated with M Tris buffer (pH 7,5) (DEAε-Trisacryl, 7.5 x 1.8 cm). melt Separation was performed with this buffer and 0-300 al&l sulfate in the same buffer for 8 hours. A linear gradient of ammonium solution was used.
カラム画分は、250μlのカラムタンパク質両分を、0.4M硫酸アンモニウ ムを含む0.2M トリス緩衝液(pH7,5)中のトリアセテート(I)の4 vaglml G液250μlとインキュベートすることにより、エステラー ゼ活性について検定した。周囲温度で18時間後、この溶液を125μlのクロ ロホルムで抽出し、HPLCで澗べた。For column fractionation, 250 μl of both column protein fractions were diluted with 0.4 M ammonium sulfate. 4 of triacetate (I) in 0.2 M Tris buffer (pH 7.5) containing By incubating with 250 μl of vaglml G solution, the ester The enzyme activity was assayed. After 18 hours at ambient temperature, this solution was poured into a 125 μl clot. It was extracted with loform and analyzed by HPLC.
生成物(II)への(Hの80%転化を示した2つのタンパク質画分を単離し、 両方ともジアセテート(1■)および([[Dの混合物中の位置異性体([[D か11%以下であった。場合により、カラムタンパク質画分を限外濾過で濃縮し 、タンパク質の濃度を測定した(M、M、 Bradford、 Anal、 BiocheIL、 1974.72.248−254に記載の方法)。Two protein fractions that showed 80% conversion of (H) to product (II) were isolated; Both regioisomers ([[D It was less than 11%. Optionally, concentrate the column protein fraction by ultrafiltration. , measured the protein concentration (M, M, Bradford, Anal, BiocheIL, 1974.72.248-254 method).
酵素調製物による位置選択的エステル加水分解1.2M トリス緩衝液(pH7 ,5)中のトリアセテート(■)の4 mg/ml溶液125μ+に、2.67 mg/mlのタンパク質濃度を有する実施例3に記載した酵素調製物250μ lと、12mMトリス緩衝液(pH7,5)中の4M硫酸アンモニウム溶液12 5μlを加えた。穏やかに混合した後、反応混合物を20℃で4時間インキュベ ートし、生成物を125μlのクロロホルムで抽出し、)fPLcで検定した。Regioselective ester hydrolysis with enzyme preparation 1.2M Tris buffer (pH 7) , 5) to a 4 mg/ml solution of triacetate (■) in 125μ+, 2.67 250μ of the enzyme preparation described in Example 3 with a protein concentration of mg/ml l and a 4M ammonium sulfate solution in 12mM Tris buffer (pH 7,5) 12 5 μl was added. After gentle mixing, the reaction mixture was incubated at 20°C for 4 hours. The product was extracted with 125 μl of chloroform and assayed by fPLc.
ジアセテート([Dへの基質([)の97%転化が見られ、生成物(II)対そ の位置異性体(I[Dの比は955で酵素触媒によるエステル加水分解に対する 硫酸アンモニウムの影響実施例3に記載の方法により、3.56 mg/mlの タンパク質濃度を育するエステラーゼ調製物を得た。この250μlアリコート を12mM)リス緩衝液(pH7,5)中の4M硫硫酸アンモニウム液液125 mに溶解したトリアセテート(f) 5 mgの2つの混合物に加え、他の反応 には12mM)リス緩衝液(pH7,5) 125μlを加えた。A 97% conversion of the substrate ([) to diacetate ([D] was observed, and the product (II) versus its positional isomer (I [D ratio is 955 for enzyme-catalyzed ester hydrolysis) Effect of ammonium sulfate By the method described in Example 3, 3.56 mg/ml of Esterase preparations were obtained that increased protein concentration. A 250 μl aliquot of this (12mM) 4M ammonium sulfate solution in Lys buffer (pH 7,5) 125 In addition to the two mixtures of 5 mg of triacetate (f) dissolved in 125 μl of 12 mM) Lys buffer (pH 7.5) was added.
20°Cで19時時間中かに混合した後、この反応混合物を250μlのクロロ ホルムで抽出し、有機相をHPLCで検定した。硫酸アンモニウムの存在下での 反応はトリアセテート(I)のジアセテート(II)への71%転化を示したが 、硫酸アンモニウムの不在下では転化率か28%であった。硫酸アンモニウムの 存在下で、ジアセテー1− (r r)対その位置異性体(Iff)の比は94 ,6であり、一方硫酸アンモニウムの不在下ではその比が82:18であった。After mixing for 19 h at 20°C, the reaction mixture was diluted with 250 μl of chloride. It was extracted with form and the organic phase was analyzed by HPLC. in the presence of ammonium sulfate The reaction showed 71% conversion of triacetate (I) to diacetate (II); In the absence of ammonium sulfate, the conversion was 28%. ammonium sulfate In the presence of diacetate, the ratio of diacetate 1-(r , 6, while in the absence of ammonium sulfate the ratio was 82:18.
実施例6 臭化シアン活性化セファロースによるエステラーゼの固定化1、74 mg/m lのタンパク質濃度を有する酵素調製物を実施例3に記載したように調製し、こ の1.25m1を1.25m1の“カップリング緩衝液“ (0,1M炭酸水素 ナトリウムおよび0.5M塩化ナトリウムの溶液、pi(8,3)と混合した。Example 6 Immobilization of esterase with cyanogen bromide activated Sepharose 1,74 mg/m An enzyme preparation with a protein concentration of 1 was prepared as described in Example 3 and 1.25 ml of “coupling buffer” (0.1M hydrogen carbonate) Mixed with a solution of sodium and 0.5M sodium chloride, pi(8,3).
この溶液でのセファデックスPDIOカラムによるクロマトグラフィーは酵素の 溶液(トリス緩衝液を除いた)3.5mlをもたらした。Chromatography on a Sephadex PDIO column in this solution was performed to detect the enzyme. Provided 3.5 ml of solution (minus Tris buffer).
この溶液を製造者の指示に従って調製した0、6mlの臭化シアン活性化セファ ロース4Bに加えた。2時間混合した後、ゲルを沈降させ、上澄みを捨てた。こ のゲルに“カップリング緩衝液”中の0.1Mグリシン4mlを加え、この懸濁 液を周囲温度でさらに1.5時間混合した。その後、ゲルを順次“カップリング 緩衝液″、0.5M塩化ナトリウム溶液中のpH4,0の0.4M酢酸緩衝液、 および“カップリング緩衝液″で洗った。ゲルは懸濁状態で4℃にて貯蔵した。This solution was added to 0.6 ml of cyanogen bromide-activated separate prepared according to the manufacturer's instructions. Added to loin 4B. After mixing for 2 hours, the gel was allowed to settle and the supernatant was discarded. child Add 4 ml of 0.1 M glycine in “coupling buffer” to the gel and suspend this suspension. The solution was mixed for an additional 1.5 hours at ambient temperature. Then, the gels are sequentially “coupled” buffer", 0.4 M acetate buffer at pH 4.0 in 0.5 M sodium chloride solution, and “coupling buffer”. Gels were stored in suspension at 4°C.
実施例7 固定化した位置選択的エステラーゼの反復使用ゲル固定化酵素は実施例6に記載 したようにゲル1ml当たり5mgのタンパク質を固定化させて調製し、この1 44 mlを等量の1M硫酸アンモニウムを含む0.1Mトリス緩衝液(pH7 ,5)で洗った。このゲルに4M硫酸アンモニウム溶液72m1および0.4M トリス緩衝液(pH7,5) 72 ml中のトリアセテート([) 600 mgの溶液を加えた。Example 7 Repetitive use of immobilized regioselective esterases Gel-immobilized enzymes are described in Example 6. Prepare the gel by immobilizing 5 mg of protein per ml as described above. 44 ml of 0.1M Tris buffer (pH 7) containing an equal volume of 1M ammonium sulfate , 5). Add 72 ml of 4M ammonium sulfate solution and 0.4M ammonium sulfate solution to this gel. Triacetate ([) in 72 ml of Tris buffer (pH 7,5) 600 mg of solution was added.
この反応混合物を14°Cで5時間振とうし、その後遠心して上溝を分離した。The reaction mixture was shaken at 14°C for 5 hours and then centrifuged to separate the upper groove.
固定化酵素調製物は1M硫酸アンモニウムを含む0.1Mlリス緩衝液(pH7 ,5)でさらに洗い、合わせた上滑をクロロホルムで抽出して、乾燥および蒸発 後に透明な油403111gを得た。この油は94:6の比で(1r)と(I[ l)を含んでいることが判明した。The immobilized enzyme preparation was prepared in 0.1 Ml Lys buffer (pH 7) containing 1 M ammonium sulfate. , 5), the combined supernatant was extracted with chloroform, dried and evaporated. Afterwards 403,111 g of clear oil were obtained. This oil was prepared in a ratio of 94:6 (1r) and (I[ It was found that it contained l).
この固定化酵素は1M硫酸アンモニウムを含むo、iM+−リス緩衝液(pH7 ,5)に再懸濁し、4°Cで貯蔵した。同じバッチを上記のようにさらに9回使 用し、それぞれの場合に類似の結果を得た。The immobilized enzyme was prepared in o, iM+-Lys buffer (pH 7) containing 1M ammonium sulfate. , 5) and stored at 4°C. Use the same batch 9 more times as above. similar results were obtained in each case.
ゲル固定化酵素のアリコートは、HPLCで検定して活性および位置選択性の低 下なしに、上記条件下で16回使用できた。Aliquots of gel-immobilized enzyme were assayed by HPLC for low activity and regioselectivity. It could be used 16 times under the above conditions without any additional cleaning.
600μmの固体のフェニルセファロースCI、−4Bゲルに4M硫酸アンモニ ウム溶液625μIおよび0.4M トリス緩衝液(pH7,5) 625μm を加えた。これに、実施例3のように調製した1、 74 mg/mlのタンパ ク質濃度を育する酵素調製物1.25m1を加えた。この懸濁液を穏やかに周囲 温度で30分間混合し、遠心し、0.1Mhリスtll[(pH7,5)中の1 M硫酸アンモニウム4+1でゲルを2回洗った。600 μm solid Phenyl Sepharose CI, -4B gel with 4M ammonium sulfate. um solution 625 μl and 0.4 M Tris buffer (pH 7,5) 625 μm added. This was supplemented with 1,74 mg/ml protein prepared as in Example 3. 1.25 ml of enzyme preparation to increase protein concentration was added. Gently swirl this suspension around Mix for 30 min at The gel was washed twice with M ammonium sulfate 4+1.
要約 抗ウィルス活性を育する化合物の製造に宵月な中間体の製造法を開示する。summary Disclosed is a method for producing intermediates useful for producing compounds that exhibit antiviral activity.
Claims (5)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB909004647A GB9004647D0 (en) | 1990-03-01 | 1990-03-01 | Pharmaceuticals |
GB9004647.5 | 1990-03-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH05503428A true JPH05503428A (en) | 1993-06-10 |
Family
ID=10671861
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP3505507A Pending JPH05503428A (en) | 1990-03-01 | 1991-02-21 | pharmaceuticals |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0518902A1 (en) |
JP (1) | JPH05503428A (en) |
AU (1) | AU645543B2 (en) |
CA (1) | CA2076628A1 (en) |
GB (1) | GB9004647D0 (en) |
IE (1) | IE910667A1 (en) |
NZ (1) | NZ237234A (en) |
PT (1) | PT96900A (en) |
WO (1) | WO1991013162A1 (en) |
ZA (1) | ZA911435B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993003166A1 (en) * | 1991-08-01 | 1993-02-18 | Beecham Group Plc | Process for the preparation of 2-acetoxy-methyl-1,4-butanediole-1-acetate |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3485225D1 (en) * | 1983-08-18 | 1991-12-05 | Beecham Group Plc | ANTIVIRAL GUANINE DERIVATIVES. |
EP0182024B1 (en) * | 1984-09-20 | 1991-04-03 | Beecham Group Plc | Purine derivatives and their pharmaceutical use |
-
1990
- 1990-03-01 GB GB909004647A patent/GB9004647D0/en active Pending
-
1991
- 1991-02-21 CA CA002076628A patent/CA2076628A1/en not_active Abandoned
- 1991-02-21 WO PCT/GB1991/000275 patent/WO1991013162A1/en not_active Application Discontinuation
- 1991-02-21 JP JP3505507A patent/JPH05503428A/en active Pending
- 1991-02-21 EP EP91904921A patent/EP0518902A1/en not_active Withdrawn
- 1991-02-21 AU AU73362/91A patent/AU645543B2/en not_active Ceased
- 1991-02-27 ZA ZA911435A patent/ZA911435B/en unknown
- 1991-02-27 IE IE066791A patent/IE910667A1/en unknown
- 1991-02-27 NZ NZ237234A patent/NZ237234A/en unknown
- 1991-02-27 PT PT96900A patent/PT96900A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU7336291A (en) | 1991-09-18 |
CA2076628A1 (en) | 1991-09-02 |
PT96900A (en) | 1991-10-31 |
WO1991013162A1 (en) | 1991-09-05 |
IE910667A1 (en) | 1991-09-11 |
AU645543B2 (en) | 1994-01-20 |
NZ237234A (en) | 1992-10-28 |
GB9004647D0 (en) | 1990-04-25 |
EP0518902A1 (en) | 1992-12-23 |
ZA911435B (en) | 1992-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1984003714A1 (en) | Process for biochemical optical resulution of cyclopentenolone derivative | |
JPH084515B2 (en) | Method for producing organic compound | |
US5888804A (en) | Processes for production of optically active quinuclidinol | |
WO2007026860A1 (en) | METHOD FOR PRODUCTION OF OPTICALLY ACTIVE α-HYDROXYCARBOXYLIC ACID | |
AU674945B2 (en) | Enantioselective hydrolysis of ketoprofen esters by (beauveria bassiana) and enzymes derived therefrom | |
JPH05503428A (en) | pharmaceuticals | |
JP2010532992A (en) | Microbial kinetic resolution of ethyl 3,4-epoxybutyrate | |
WO2003097851A1 (en) | Process for producing optically active alkylcarboxylic acid derivative | |
WO1993003166A1 (en) | Process for the preparation of 2-acetoxy-methyl-1,4-butanediole-1-acetate | |
JPH08507683A (en) | Methods of using it for esterase and biotransformation | |
JPS6363396A (en) | Production of d-2-(6-methoxy-2-naphthyl)propionic acid | |
JP2750017B2 (en) | Novel enzyme, method for producing the same, and method for producing optically active (R) -2-hydroxy-4-phenylbutyric acid | |
JPH04356195A (en) | Production of azetidinone derivative | |
CN117586979A (en) | Acyltransferase mutant with improved enzyme activity | |
JP4711367B2 (en) | Method for producing optically active amino alcohol derivative | |
Urbanczyk et al. | Hydrolytic properties of lipase produced by entomopathogenic fungus Zoophthora (Erynia) ovispora | |
JPH01222798A (en) | Production of optically active carboxylic acid and antipode ester thereof | |
JPH01117792A (en) | Production of 3(r)-hydroxybutyric acid ester | |
JPH04252189A (en) | Production of benzenedicarboxlic monoester or derivative thereof | |
JPH0545235B2 (en) | ||
JPH04349890A (en) | Production of monoacetylpolyamine | |
JPS61205498A (en) | Production of axial asymmetric compound | |
JPH04262787A (en) | Method for production of acetate ester of diol and polyol in substantially aqueous medium using corynebacterium oxidance | |
JPS5921600B2 (en) | Method for producing D(-)-β-hydroxyisobutyric acid | |
JPH10165195A (en) | Production of (s)-4-hydroxy-2-pyrrolidone |